Loading this company
Legend Biotech Corporation
LEGNPrices in USD
TickerWorth ScoreB59/100
What we think
Priced within our range of $9.06 to $31.95.
Price
$18.48USD down −$1.32 (−6.67%)
Quoted · Prices are delayed.
Why did it move today?
Nothing we can cite explains today’s move for this company.
Is it cheap?
Our range from 3 models, on today’s numbers
$9.06–$31.95
What the price needs: revenue growth of 3.8%/yr for 5 years (our model assumes 16.6%).
Led by discounted cash flow (DCF) · Steady cash-flow business
Price $18.48Priced · Prices are delayed.
Is it a good business?
- Valuation100 out of 100
- Growth100 out of 100
- Financial health100 out of 100
- Past performance0 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$45.62 across 13 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). It operates in the Biotechnology industry (Healthcare sector), headquartered in United States. The company employs roughly 3,200 people.
Key stats
52-week range$16.24–$37.50
- Open
- $19.69
- Day high
- $19.77
- Day low
- $18.40
- Previous close
- $19.80
- Volume
- 2,961,655 · 1.26× avg
- Average volume
- 2,344,206
- Market cap
- $3,594,145,792.00
- P/E (TTM)
- —
- Earnings per share
- −$0.52
- Beta
- 0.57
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
No filings or corporate activity on file in the recent window.
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Sanders Corazon (Corsee) D.Open-market sale · $258,920.20
- Salovey PeterGrant / award ·
Not investment advice. TickerWorth Score is a model output.